Immune checkpoint inhibitors, including monoclonal antibodies against PD-1, PD-L1 and CTLA-4, are one of the most successful classes of immunotherapeutic agents that produce durable anti-tumor immune responses by blocking immunosuppressive receptors [6]. Here, CD274 is linked to neoplasm.